Stanford University School of Medicine, 780 Welch Rd. Suite 208E, Palo Alto, CA 94040, USA.
Pain Med. 2010 Apr;11(4):617-21. doi: 10.1111/j.1526-4637.2010.00807.x. Epub 2010 Mar 4.
Oral sodium channel blockers have shown mixed results in randomized controlled trials despite the known importance of sodium channels in generating pain. We hypothesized that differing baseline pain qualities (e.g. "stabbing" vs "dull") might define specific subgroups responsive to intravenous (IV) lidocaine-a potent sodium channel blocker.
A prospective cohort study of 71 patient with chronic pain suspected of being neuropathic were recruited between January 2003 and July 2007 and underwent lidocaine infusions at Stanford University Hospital in a single-blind nonrandomized fashion. Baseline sensory pain qualities were measured with the Short-Form McGill Pain Questionnaire (SF-MPQ). Pain intensity was measured with a visual analog scale (VAS).
Factor analysis demonstrated two underlying pain quality factors among SF-MPQ sensory items: a heavy pain and a stabbing pain. Baseline heavy pain quality, but not stabbing quality predicted subsequent relief of pain intensity in response to lidocaine. In contrast, these factors did not predict divergent analgesic responses to placebo infusions. In response to each 1 mcg/mL increase in lidocaine plasma level, patients with high heavy pain quality drop their VAS 0.24 (95% CI 0.05-0.43) more points than those with low heavy pain quality (P < 0.013).
"Heavy" pain quality may indentify patients with enhanced lidocaine responsiveness. Pain quality may identify subgroups among patients with suspected neuropathic pain responsive to IV lidocaine. Further investigation is warranted to validate and extend these findings.
尽管钠离子通道在产生疼痛方面具有重要作用,但口腔钠离子通道阻滞剂在随机对照试验中的结果喜忧参半。我们假设,不同的基线疼痛性质(例如“刺痛”与“钝痛”)可能会定义对静脉注射利多卡因(一种有效的钠离子通道阻滞剂)有反应的特定亚组。
2003 年 1 月至 2007 年 7 月,我们对斯坦福大学医院的 71 例慢性疼痛患者进行了一项前瞻性队列研究,这些患者疑似患有神经性疼痛,以单盲非随机的方式接受了利多卡因输注。使用简短 McGill 疼痛问卷(SF-MPQ)测量基线感觉疼痛性质。使用视觉模拟评分(VAS)测量疼痛强度。
因子分析表明,SF-MPQ 感觉项目中有两个潜在的疼痛质量因子:沉重的疼痛和刺痛的疼痛。基线沉重疼痛质量,但不是刺痛质量,预测了随后对利多卡因的疼痛强度缓解。相比之下,这些因素并不能预测对安慰剂输注的不同镇痛反应。随着利多卡因血浆水平每增加 1 mcg/mL,疼痛质量高的患者 VAS 下降 0.24(95%CI 0.05-0.43)点,而疼痛质量低的患者 VAS 下降 0.24 点(95%CI 0.05-0.43)点(P <0.013)。
“沉重”的疼痛质量可能可以识别对利多卡因反应增强的患者。疼痛质量可能可以识别疑似神经性疼痛患者中对静脉注射利多卡因有反应的亚组。需要进一步的调查来验证和扩展这些发现。